For that one positive JAMA (Look at the long list of conflicts of interest in that puff piece) , there are multiple other peer reviewed pieces totally discrediting the phase 3 trial and DCVAX Learn how to read more than ONE thing. Here are just a couple.
https://academic.oup.com/neuro-oncology/article/25/4/631/6958519?login=false "To conclude, stringently designed and executed prospective randomized clinical trials remain the gold standard for evaluation of efficacy of novel treatments. Control of known, but also unknown, confounders are crucial in clinical trials, and the present analyses of the DCVax-L trial offer neither"
"9. Conclusion This dendritic vaccine trial has several limitations. These limitations include changing the primary endpoint (OS instead of PFS), creating a new study population (recurrent glioblastoma), conducting unplanned analyses, using external controls in a design originally intended to be randomized, all changes occurring years after the trial finished enrollment. The selected external controls likely included patients with less favorable outcomes, which opposes the “fit-for-purpose” criteria usually applied in selecting external controls. Therefore, the purported survival benefit from the vaccine is unreliable."
Market Data 
Markets 
AI
